Hedge Fund - Partner Fund Management

You can access the original SEC filing by clicking here.

Billionaire hedge fund titan Leon Cooperman told CNBC on Tuesday he won't enter a deal with regulators to settle insider trading charges and he insisted he has always followed the law.

Chris James' Partner Fund Management revealed a 5.1% position in Blueprint Medicines Corp (NASDAQ:BPMC) last week.

There is no doubt that some hedge funds’ 13F filings disclose rich trading ideas, but these filings are generally considered delayed and irrelevant.

Christopher Medlock James' Partner Fund Management recently initiated a position in Heron Therapeutics Inc (NASDAQ:HRTX), together with its affiliated funds, according to a 13G form filed with the Securities...

Headquartered in San Francisco, Partner Fund Management was established in 2004 by Christopher Medlock James.

Christopher Medlock James', San Francisco-based, hedge fund Partner Fund Management has raised its position in Orexigen Therapeutics, Inc. (NASDAQ:OREX), a new filing with the SEC showed.

In the eyes of many traders, hedge funds are assumed to be useless, outdated financial tools of a forgotten age.

In the 21st century investor’s toolkit, there are a multitude of indicators shareholders can use to analyze their holdings. A duo of the most innovative are hedge fund and insider trading sentiment.